Table 3.
Device usage at 6 months in patient subgroups (per-protocol population)
| Patient subgroup | Home therapy group | Control group | p value* |
|---|---|---|---|
| Usage (h/day) | Usage (h/day) | ||
| Age ≤50 years |
(n = 31) 4.25 ± 2.11 (3.48, 5.03) |
(n = 38) 4.08 ± 2.34 (3.32, 4.85) |
0.76 |
| Age >50 years |
(n = 58) 4.45 ± 2.02 (3.92, 4.98) |
(n = 55) 4.48 ± 2.25 (3.87, 5.09) |
|
| Male |
(n = 75) 4.47 ± 2.07 (3.99, 4.94) |
(n = 76) 4.43 ± 2.18 (3.94, 4.93) |
0.91 |
| Female |
(n = 14) 3.93 ± 1.93 (2.81, 5.05) |
(n = 17) 3.80 ± 2.71 (2.40, 5.19) |
|
| Moderate OSA |
(n = 44) 3.91 ± 1.97 (3.31, 4.51) |
(n = 44) 4.26 ± 2.04 (3.64, 4.88) |
0.20 |
| Severe OSA |
(n = 45) 4.84 ± 2.03 (4.23, 5.45) |
(n = 49) 4.37 ± 2.50 (3.65, 5.09) |
|
| Baseline ESS score <13 |
(n = 56) 4.33 ± 2.12 (3.77, 4.90) |
(n = 55) 4.40 ± 2.39 (3.76, 5.05) |
0.62 |
| Baseline ESS score ≥13 |
(n = 31) 4.46 ± 2.00 (3.72, 5.19) |
(n = 35) 4.18 ± 2.14 (3.45, 4.92) |
Values are mean ± standard deviation (95% confidence interval)
*ANOVA p value for the interaction effect of the subgroup × treatment group